Afinitor is an anti-cancer drug owned by Novartis. The active ingredient in Afinitor is everolimus. The drug received market authorization on 30th March 2009 and is available in tablet form for oral administration.
Afinitor is currently patented under a total of seven patents. Out of these, four have already expired. The last patent, US9006224 titled 'Neuroendocrine tumor treatment', is set to expire on July 1st, 2028. Therefore, the generic version of Afinitor is expected to hit the market after this date.
Afinitor is primarily used in the treatment of patients with progressive neuroendocrine tumors of pancreatic origin that are unresectable, locally advanced, or metastatic. Moreover, it can also be used for the treatment of advanced renal cell carcinoma, following the failure of treatment with Sunitinib or Sorafenib, and advanced hormone receptor-positive, HER2-negative breast cancer in combination with Exemestane after the failure of treatment with Letrozole or Anastrozole. Afinitor is also effective for patients with tuberous sclerosis complex who have subependymal giant cell astrocytoma that requires therapeutic intervention but cannot be curatively resected.
Afinitor currently holds three unexpired patents: US8410131 titled 'Cancer treatment' expiring on November 1, 2025, US8410131*PED titled 'Cancer treatment' expiring on May 1, 2026, and finally US9006224 titled 'Neuroendocrine tumor treatment' expiring on July 1, 2028. The Afinitor generic is anticipated to be available after the final patent expires on July 1, 2028. Below are the details of the patent: